Bayer Anticipates High-speed Growth After Merger (China)
This article was originally published in PharmAsia News
Bayer Schering Pharmaceuticals China expects to maintain growth of over 30 percent in the market, as the merger of the healthcare units of Bayer and Schering nears completion. Liam Condon, managing director of Bayer Healthcare China and chief of Bayer Schering Pharmaceuticals China, reports Bayer Schering saw growth of about 50 percent in 2005 and is targeting a further 30 to 50 percent this year. "Our business scale (this year) will be much larger than last year's for sure," says Condon. U.S. healthcare industry research company IMS Health says that China's pharmaceutical market will grow by 14.4 percent this year. The Chinese pharmaceutical market is shifting focus from antibiotics to treatment for cancers, cardiovascular and cerebrovascular diseases, and diabetes. Bayer Schering also plans to introduce more of its blockbuster medicines to the Chinese market. (Click here for more
You may also be interested in...
The Phase III FIDELIO trial of finerenone has been a success but analysts want to see some actual data before declaring it an unqualified one.
Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.
Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.